Evidence map›Paper›PMID 41462859›Full record

ArticleBiomedicines2025

Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience.

Abdullah Esmail, Yazan Hamadneh, Bayan Khasawneh, Maryam Al-Rawi, Ebtesam Al-Najjar, Vikram Dhillon, Ahmad Alhaj, Yaser Rayyan, Maen Abdelrahim

Abstract read
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdullah EsmailSection of GI Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2337-8351
Yazan HamadnehFaculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Bayan KhasawnehSection of GI Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX 77030, USA.
Maryam Al-RawiFaculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Ebtesam Al-NajjarSection of GI Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX 77030, USA.
Vikram DhillonSection of GI Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX 77030, USA.
Ahmad AlhajFaculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Yaser RayyanFaculty of Medicine, The University of Jordan, Amman 11942, Jordan.
Maen AbdelrahimSection of GI Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabbevacizumabChild–Pughhepatocellular carcinomaimmune checkpoint inhibitorslocoregional therapyoverall survivalprogression-free survivalreal-world evidenceunresectable HCC

Identifiers

PMID41462859
PMCPMC12730803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.